Trial Profile
NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adaptive T-cell Therapy (Adenovirus, Yeast, Fusion Protein Vaccine) in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Bevacizumab (Primary) ; Capecitabine (Primary) ; Cyclophosphamide (Primary) ; ETBX 011 (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; GI 4000 (Primary) ; High affinity CD-expressing natural killer cell therapy ImmunityBio (Primary) ; Inbakicept (Primary) ; Omega-3-acid ethyl esters (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms QUILT-3.060
- Sponsors ImmunityBio; NantKwest
- 10 Aug 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 10 Aug 2020 Planned primary completion date changed from 1 Nov 2018 to 1 Dec 2020.
- 04 Jan 2018 Status changed from recruiting to active, no longer recruiting.